Pharmacogenetic Study of Deferasirox, an Iron Chelating Agent

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Lee, Ji Won ^a   Kang, Hyoung Jin ^a   Choi, Ji Yeob ^b   Kim, Nam Hee ^a   Jang, Mi Kyung ^a   Yeo, Chang Woo ^c   Lee, Sang Seop ^c   Kim, Hyery ^a   Park, June Dong ^a   Park, Kyung Duk ^a   Shin, Hee Young ^a   Shin, Jae Gook ^c   Ahn, Hyo Seop ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c Inje University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CREATININE; DEFERASIROX; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A; GLUCURONOSYLTRANSFERASE 1A1; MULTIDRUG RESISTANCE PROTEIN 2; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ALLELE; ARTICLE; BODY WEIGHT; CHILD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DNA POLYMORPHISM; DRUG TRANSPORT; DRUG WITHDRAWAL; ENZYME METABOLISM; FEMALE; GENE; GENE DELETION; GENE FUNCTION; GENETIC RISK; GENETIC VARIABILITY; GLUCURONIDATION; HAPLOTYPE; HIGH RISK POPULATION; HOMOZYGOSITY; HUMAN; INFANT; IRON OVERLOAD; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; TRANSFUSION; UGT1A1;

ADOLESCENT; ATP-BINDING CASSETTE TRANSPORTERS; BENZOATES; CHILD; CHILD, PRESCHOOL; CREATININE; FEMALE; GLUCURONOSYLTRANSFERASE; HUMANS; INFANT; IRON CHELATING AGENTS; LIVER; MALE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; TRIAZOLES; YOUNG ADULT;

EID: 84878521432     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064114     Document Type: Article

References (44)

1. Evens AM, Mehta J, Gordon LI, (2004) Rust and corrosion in hematopoietic stem cell transplantation: the problem of iron and oxidative stress. Bone Marrow Transplant 34: 561-571.
2. Altes A, Remacha AF, Sarda P, Baiget M, Sureda A, et al. (2007) Early clinical impact of iron overload in stem cell transplantation. A prospective study. Ann Hematol 86: 443-447.
3. Altes A, Remacha AF, Sureda A, Martino R, Briones J, et al. (2002) Iron overload might increase transplant-related mortality in haematopoietic stem cell transplantation. Bone Marrow Transplant 29: 987-989.
4. Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, et al. (2007) Prognostic impact of elevated pre-transplant serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 109: 4586-4588.
5. Lee JW, Kang HJ, Kim EK, Kim H, Shin HY, et al. (2009) Effect of iron overload and iron-chelating therapy on allogeneic hematopoietic SCT in children. Bone Marrow Transplant 44: 793-797.
6. Miceli MH, Dong L, Grazziutti ML, Fassas A, Thertulien R, et al. (2006) Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients. Bone Marrow Transplant 37: 857-864.
7. Morado M, Ojeda E, Garcia-Bustos J, Aguado MJ, Arrieta R, et al. (2000) BMT: Serum Ferritin as Risk Factor for Veno-occlusive Disease of the Liver. Prospective Cohort Study. Hematol 4: 505-512.
8. Cario H, Janka-Schaub G, Janssen G, Jarisch A, Strauss G, et al. (2007) Recent developments in iron chelation therapy. Klin Padiatr 219: 158-165.
9. Kushner JP, Porter JP, Olivieri NF (2001) Secondary iron overload. Hematology Am Soc Hematol Educ Program: 47-61.
10. Olivieri NF, Brittenham GM, (1997) Iron-chelating therapy and the treatment of thalassemia. Blood 89: 739-761.
11. Won SC, Han DK, Seo JJ, Chung NG, Park SK, et al. (2010) Efficacy and safety of deferiprone (Ferriprox), an oral iron-chelating agent, in pediatric patients. Korean J Hematol 45: 58-61.
12. Cappellini MD, Bejaoui M, Agaoglu L, Porter J, Coates T, et al. (2007) Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clin Ther 29: 909-917.
13. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, et al. (2006) A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 107: 3455-3462.
14. Cappellini MD, Porter J, El-Beshlawy A, Li CK, Seymour JF, et al. (2010) Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica 95: 557-566.
15. Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, et al. (2006) Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 91: 873-880.
16. Porter J, Galanello R, Saglio G, Neufeld EJ, Vichinsky E, et al. (2008) Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol 80: 168-176.
17. Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, et al. (2007) A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 136: 501-508.
18. Aslam N, Mettu P, Marsano-Obando LS, Martin A, (2010) Deferasirox induced liver injury in haemochromatosis. J Coll Physicians Surg Pak 20: 551-553.
19. Galanello R, Piga A, Forni GL, Bertrand Y, Foschini ML, et al. (2006) Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica 91: 1343-1351.
20. Kontoghiorghes GJ, (2007) Deferasirox: uncertain future following renal failure fatalities, agranulocytosis and other toxicities. Expert Opin Drug Saf 6: 235-239.
21. Kontoghiorghes GJ, (2008) Update on toxicity and efficacy aspects of treatment with deferasirox and its implication on the morbidity and mortality of transfused iron loaded patients. Expert Opin Drug Saf 7: 645-646.
22. Gardiner SJ, Begg EJ, (2006) Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 58: 521-590.
23. Bruin GJ, Faller T, Wiegand H, Schweitzer A, Nick H, et al. (2008) Pharmacokinetics, distribution, metabolism, and excretion of deferasirox and its iron complex in rats. Drug Metab Dispos 36: 2523-2538.
24. Mao Q, Unadkat JD, (2005) Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J 7: E118-133.
25. Yea SS, Lee SS, Kim WY, Liu KH, Kim H, et al. (2008) Genetic variations and haplotypes of UDP-glucuronosyltransferase 1A locus in a Korean population. Ther Drug Monit 30: 23-34.
26. Lee SS, Jeong HE, Yi JM, Jung HJ, Jang JE, et al. (2007) Identification and functional assessment of BCRP polymorphisms in a Korean population. Drug Metab Dispos 35: 623-632.
27. Choi JH, Ahn BM, Yi J, Lee JH, Nam SW, et al. (2007) MRP2 haplotypes confer differential susceptibility to toxic liver injury. Pharmacogenet Genomics 17: 403-415.
28. Stephens M, Smith NJ, Donnelly P, (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68: 978-989.
29. Lewontin RC, (1988) On measures of gametic disequilibrium. Genetics 120: 849-852.
30. Vichinsky E, Bernaudin F, Forni GL, Gardner R, Hassell K, et al. (2011) Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. Br J Haematol 154: 387-397.
31. Aydinok Y, Unal S, Oymak Y, Vergin C, Turker ZD, et al. (2012) Observational study comparing long-term safety and efficacy of Deferasirox with Desferrioxamine therapy in chelation-naive children with transfusional iron overload. Eur J Haematol 88: 431-438.
32. Jemnitz K, Heredi-Szabo K, Janossy J, Ioja E, Vereczkey L, et al. (2010) ABCC2/Abcc2: a multispecific transporter with dominant excretory functions. Drug Metab Rev 42: 402-436.
33. Poli G, (2000) Pathogenesis of liver fibrosis: role of oxidative stress. Mol Aspects Med 21: 49-98.
34. Jensen PD, Jensen FT, Christensen T, Nielsen JL, Ellegaard J, (2003) Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias. Blood 101: 91-96.
35. Cappellini MD, Bejaoui M, Agaoglu L, Canatan D, Capra M, et al. (2011) Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood 118: 884-893.
36. National Center for Biotechnology Information. GENE. Available: http://www.ncbi.nlm.nih.gov/gene/54658. Accessed: 2012 Jun 06.
37. Han JY, Lim HS, Shin ES, Yoo YK, Park YH, et al. (2006) Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 24: 2237-2244.
38. Satoh T, Ura T, Yamada Y, Yamazaki K, Tsujinaka T, et al. (2011) Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms. Cancer Sci 102: 1868-1873.
39. Shulman K, Cohen I, Barnett-Griness O, Kuten A, Gruber SB, et al. (2011) Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients. Cancer 117: 3156-3162.
40. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, et al. (2001) Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7: 2182-2194.
41. Novartis Pharmaceuticals Corporation (per FDA) (2011) Product Information: EXJADE(R) oral tablets for suspension, deferasirox oral tablets for suspension, East Hanover, NJ.
42. Akiyama Y, Fujita K, Nagashima F, Yamamoto W, Endo H, et al. (2008) Genetic testing for UGT1A1*28 and *6 in Japanese patients who receive irinotecan chemotherapy. Ann Oncol 19: 2089-2090.
43. Beutler E, Gelbart T, Demina A, (1998) Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A 95: 8170-8174.
44. Sunakawa Y, Ichikawa W, Fujita K, Nagashima F, Ishida H, et al. (2011) UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer. Cancer Chemother Pharmacol 68: 279-284.